ADAP
Adaptimmune Therapeutics plc
$0.17
+$0.02(+15.93%)
36
Overall
--
Value
36
Tech
--
Quality
Market Cap
$21.68M
Volume
157.05M
52W Range
$0.04 - $1.01
Target Price
$0.74
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Total Revenue | $14.2M | $37.8M | $59.5M | $1.1M | $4.0M | $6.1M | $27.1M | $60.3M | $178.0M | ||
| Total Revenue | $14.2M | $37.8M | $59.5M | $1.1M | $4.0M | $6.1M | $27.1M | $60.3M | $178.0M | ||
| COST OF GOODS SOLD | |||||||||||
| Cost of Revenue | $-87.0M | -- | -- | -- | -- | -- | -- | -- | $70.0K | ||
| GROSS PROFIT | |||||||||||
| Gross Profit | $14.2M | $37.8M | $59.5M | $1.1M | $4.0M | $6.1M | $27.1M | $60.3M | $178.0M | ||
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $87.0M | $118.5M | $141.9M | $140.9M | $137.4M | $168.4M | $188.8M | $200.0M | $236.3M | ||
| Research & Development | $63.8M | $87.4M | $98.3M | $97.5M | $91.6M | $111.1M | $127.7M | $126.5M | $149.1M | ||
| Research Expense | $63.8M | $87.4M | $98.3M | $97.5M | $91.6M | $111.1M | $127.7M | $126.5M | $149.1M | ||
| Selling, General & Administrative | $23.2M | $31.1M | $43.6M | $43.4M | $45.8M | $57.3M | $63.4M | $73.5M | $87.3M | ||
| General & Administrative Expenses | $23.2M | $31.1M | $43.6M | $43.4M | $45.8M | $57.3M | $63.4M | $73.5M | $87.3M | ||
| Salaries & Wages | $-8.8M | $-10.8M | $-16.2M | -- | $10.4M | $20.6M | $18.2M | $11.8M | $12.1M | ||
| Depreciation & Amortization | $-3.1M | $-5.0M | $-7.2M | $7.2M | $6.6M | $5.6M | $5.3M | $9.5M | $10.8M | ||
| Depreciation & Amortization | $-3.1M | $-5.0M | $-7.2M | $7.2M | $6.6M | $5.6M | $5.3M | $9.5M | $10.8M | ||
| Amortization | $-160.0K | $-391.0K | $-622.0K | $838.0K | $967.0K | $937.0K | $809.0K | $-1.6M | $-996.0K | ||
| Other Operating Expenses | -- | -- | -- | $4.3M | $4.4M | $4.7M | $4.8M | $200.0M | $246.8M | ||
| OPERATING INCOME | |||||||||||
| Operating income | $-72.8M | $-80.7M | $-82.4M | $-139.8M | $-133.4M | $-162.2M | $-164.0M | $-139.7M | $-68.8M | ||
| EBITDA | $-67.4M | $-64.3M | $-87.2M | $-128.9M | $-125.8M | $-155.7M | $-154.4M | $-104.7M | $-54.3M | ||
| NON-OPERATING ITEMS | |||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | -- | -- | -- | $3.3M | ||
| Interest Income Operating | -- | -- | -- | $2.8M | $2.3M | $1.1M | $1.5M | $6.0M | -- | ||
| Intinc | $1.1M | $2.2M | $2.8M | $2.8M | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $1.1M | $2.2M | $2.8M | $2.8M | -- | -- | $-1.5M | $-6.0M | -- | ||
| Gain on Sale of Securities | -- | $-646.0K | -- | $13.0K | $89.0K | $6.0K | -- | $6.0M | $6.6M | ||
| Other Income/Expense | $-1.0M | $-8.7M | $15.5M | $-75.0K | $-1.2M | $-3.9M | $-2.8M | $-5.2M | $5.5M | ||
| Other Special Charges | $1.0M | $8.7M | $-15.5M | $75.0K | $1.2M | $3.9M | $-536.0K | $-807.0K | $-1.7M | ||
| SPECIAL ITEMS | |||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | $2.3M | $1.6M | $6.0M | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | $-2.3M | $-1.6M | $-6.0M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | $10.4M | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $-70.7M | $-69.7M | $-95.0M | $-136.9M | $-133.4M | $-162.2M | $-163.0M | $-112.5M | $-63.9M | ||
| Pre-Tax Income | $-70.7M | $-69.7M | $-95.0M | $-136.9M | $-129.9M | $-157.3M | $-163.0M | $-112.5M | $-67.2M | ||
| INCOME TAX | |||||||||||
| Tax Provision | $892.0K | $451.0K | $497.0K | $242.0K | $162.0K | $791.0K | $2.5M | $1.3M | $3.6M | ||
| NET INCOME | |||||||||||
| Net Income | $-71.6M | $-70.1M | $-95.5M | $-137.2M | $-130.1M | $-158.1M | $-165.5M | $-113.9M | $-70.8M | ||
| Net Income (Continuing Operations) | $-71.6M | $-70.1M | $-95.5M | $-137.2M | $-130.1M | $-158.1M | $-165.5M | $-113.9M | $-70.8M | ||
| Net Income (Discontinued Operations) | $-71.6M | $-70.1M | $-95.5M | $-137.2M | $-130.1M | $-158.1M | $-165.5M | $-113.9M | $-70.8M | ||
| Net Income (Common Stockholders) | $-71.6M | $-70.1M | $-95.5M | $-137.2M | $-130.1M | $-158.1M | $-165.5M | $-113.9M | $-70.8M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | $-50.2M | ||
| TOTALS | |||||||||||
| Total Expenses | -- | $118.5M | $141.9M | $140.9M | $137.4M | $168.4M | $188.8M | $200.0M | $236.4M | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | $424.7M | $527.6M | $584.3M | $629.8M | $854.8M | $934.8M | $967.2M | $1.2B | $1.5B | ||
| Average Shares Outstanding (Diluted) | $421.1M | $539.5M | $597.0M | $629.8M | $854.8M | $934.8M | $967.2M | $1.2B | $1.5B | ||
| Shares Outstanding | $424.8M | $562.1M | $628.1M | $780.5M | $930.8M | $265.1M | $991.8M | $1.5B | $1.5B | ||
| Basic EPS | -- | -- | -- | $-0.22 | $-0.15 | $-0.17 | $-0.17 | $-0.54 | $-0.05 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-0.22 | $-0.15 | $-0.17 | $-0.17 | $-0.09 | $-0.05 | ||
| Diluted EPS | $-0.17 | $-0.13 | $-0.16 | $-0.22 | $-0.15 | $-0.17 | $-0.17 | $-0.54 | $-0.05 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-0.17 | $-0.17 | $-0.09 | $-0.05 | ||
| OTHER METRICS | |||||||||||
| Development Expense | $-3.0M | $-1.0M | $-210.0K | $4.6M | $889.0K | $562.0K | $2.3M | $1.8M | $52.0K | ||
| Gain On Sale Of P P E | $-122.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $23.2M | $31.1M | $43.6M | $43.4M | $45.8M | $57.3M | $63.4M | $73.5M | $87.3M | ||
| Rent And Landing Fees | $23.2M | $31.1M | $43.6M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | $2.3M | $1.6M | $6.0M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ADAP | $0.17 | +15.9% | 157.05M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Adaptimmune Therapeutics plc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW